Consolidation with a busulfan-containing regimen followed by stem cell transplantation in infants with poor prognosis stage 4 neuroblastoma
- 26 April 2000
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 25 (9) , 937-942
- https://doi.org/10.1038/sj.bmt.1702376
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Gain of Chromosome Arm 17q and Adverse Outcome in Patients with NeuroblastomaNew England Journal of Medicine, 1999
- Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institutionBone Marrow Transplantation, 1999
- Pharmacokinetics of intravenous busulfan and evaluation of the bioavailability of the oral formulation in conditioning for haematopoietic stem cell transplantationBone Marrow Transplantation, 1998
- Genetic Staging of Unresectable or Metastatic Neuroblastomain Infants: a Pediatric Oncology Group StudyJNCI Journal of the National Cancer Institute, 1997
- Formulation and stability of busulfan for intravenous administration in high-dose chemotherapyCancer Chemotherapy and Pharmacology, 1996
- Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantationCancer Chemotherapy and Pharmacology, 1995
- What Is the prognostic value of osteomedullary uptake on MIBG scan in neuroblastoma patients under one year of age?Medical and Pediatric Oncology, 1994
- Venocclusive Disease of the Liver after Bone Marrow Transplantation: Diagnosis, Incidence, and Predisposing FactorsHepatology, 1984
- Estimation of confidence limits for the cumulative probability of survival in life table analysisJournal of Chronic Diseases, 1978
- Asymptotically Efficient Rank Invariant Test ProceduresJournal of the Royal Statistical Society. Series A (General), 1972